Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Jun;64(6):736–741. doi: 10.1136/jnnp.64.6.736

Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis

S Edwards 1, M Zvartau 1, H Clarke 1, W Irving 1, L Blumhardt 1
PMCID: PMC2170117  PMID: 9647301

Abstract

BACKGROUND—Although the risk of clinical attacks of multiple sclerosis seems to be significantly increased with viral upper respiratory tract infections (URTI), serological evidence for the reported association remains controversial. In addition, although MRI is six to 10 times more sensitive than clinical exacerbations in indexing disease activity, any possible association between URTI and MRI activity has yet to be investigated.
OBJECTIVES—To examine the relation between URTI and disease activity, in multiple sclerosis patients participating in a placebo controlled trial of interferon β-1a, as indexed both by clinical exacerbation rate and by the number and volume of gadolinium - diethylenetriaminepenta acetic acid (Gd-DTPA) enhancing lesions on MRI. "At risk" periods were defined around symptomatic URTI, with or without serological confirmation.
RESULTS—The relative risk of clinical relapse for serologically unconfirmed symptomatic URTI was 2.1 (p=0.004). Raised antiviral antibody titres conferred a relative risk of multiple sclerosis exacerbations that was 3.4 times higher than the "not at risk" periods (annual attack rates of 5.7 v 1.6, respectively, p=0.006). There was no definite relation between the number or the volume of active lesions on MRI and either symptomatic or serologically defined at risk periods.
CONCLUSIONS—These results confirm the previously reported association between viral infections and multiple sclerosis exacerbations and indicate that the relative risk may be even higher when viral infection is serologically confirmed. However, the results, perhaps because of the confounding effects of interferon β-1a, do not provide convincing evidence of increased blood-brain barrier breakdown or inflammation during periods of virally induced immune stimulation.



Full Text

The Full Text of this article is available as a PDF (129.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen I., Brankin B. Pathogenesis of multiple sclerosis--the immune diathesis and the role of viruses. J Neuropathol Exp Neurol. 1993 Mar;52(2):95–105. doi: 10.1097/00005072-199303000-00001. [DOI] [PubMed] [Google Scholar]
  2. Andersen O., Lygner P. E., Bergström T., Andersson M., Vahlne A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol. 1993 Jul;240(7):417–422. doi: 10.1007/BF00867354. [DOI] [PubMed] [Google Scholar]
  3. Anderson M. J., Higgins P. G., Davis L. R., Willman J. S., Jones S. E., Kidd I. M., Pattison J. R., Tyrrell D. A. Experimental parvoviral infection in humans. J Infect Dis. 1985 Aug;152(2):257–265. doi: 10.1093/infdis/152.2.257. [DOI] [PubMed] [Google Scholar]
  4. Barkhof F., Scheltens P., Frequin S. T., Nauta J. J., Tas M. W., Valk J., Hommes O. R. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol. 1992 Nov;159(5):1041–1047. doi: 10.2214/ajr.159.5.1414773. [DOI] [PubMed] [Google Scholar]
  5. Burks J. S., DeVald B. L., Jankovsky L. D., Gerdes J. C. Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients. Science. 1980 Aug 22;209(4459):933–934. doi: 10.1126/science.7403860. [DOI] [PubMed] [Google Scholar]
  6. Capra R., Marcianò N., Vignolo L. A., Chiesa A., Gasparotti R. Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis. Arch Neurol. 1992 Jul;49(7):687–689. doi: 10.1001/archneur.1992.00530310029008. [DOI] [PubMed] [Google Scholar]
  7. Cook S. D., Dowling P. C., Russell W. C. Multiple sclerosis and canine distemper. Lancet. 1978 Mar 18;1(8064):605–606. doi: 10.1016/s0140-6736(78)91047-4. [DOI] [PubMed] [Google Scholar]
  8. Elian M., Nightingale S., Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies. J Neurol Neurosurg Psychiatry. 1990 Oct;53(10):906–911. doi: 10.1136/jnnp.53.10.906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Field E. J., Cowshall S., Narang H. K., Bell T. M. Viruses in multiple sclerosis? Lancet. 1972 Aug 5;2(7771):280–281. doi: 10.1016/s0140-6736(72)91714-x. [DOI] [PubMed] [Google Scholar]
  10. Filippi M., Horsfield M. A., Campi A., Mammi S., Pereira C., Comi G. Resolution-dependent estimates of lesion volumes in magnetic resonance imaging studies of the brain in multiple sclerosis. Ann Neurol. 1995 Nov;38(5):749–754. doi: 10.1002/ana.410380509. [DOI] [PubMed] [Google Scholar]
  11. Frank J. A., Stone L. A., Smith M. E., Albert P. S., Maloni H., McFarland H. F. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol. 1994;36 (Suppl):S86–S90. doi: 10.1002/ana.410360719. [DOI] [PubMed] [Google Scholar]
  12. Goswami K. K., Morris R. J., Rastogi S. C., Lange L. S., Russell W. C. A neutralising monoclonal antibody against a paramyxovirus reacts with a brain antigen. J Neuroimmunol. 1985 Jul;9(1-2):99–108. doi: 10.1016/s0165-5728(85)80010-2. [DOI] [PubMed] [Google Scholar]
  13. Kastrukoff L. F., Oger J. J., Hashimoto S. A., Sacks S. L., Li D. K., Palmer M. R., Koopmans R. A., Petkau A. J., Berkowitz J., Paty D. W. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology. 1990 Mar;40(3 Pt 1):479–486. doi: 10.1212/wnl.40.3_part_1.479. [DOI] [PubMed] [Google Scholar]
  14. Kennedy P. G., Steiner I. On the possible viral aetiology of multiple sclerosis. QJM. 1994 Sep;87(9):523–528. doi: 10.1093/oxfordjournals.qjmed.a068963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kermode A. G., Thompson A. J., Tofts P., MacManus D. G., Kendall B. E., Kingsley D. P., Moseley I. F., Rudge P., McDonald W. I. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 1990 Oct;113(Pt 5):1477–1489. doi: 10.1093/brain/113.5.1477. [DOI] [PubMed] [Google Scholar]
  16. Koopmans R. A., Li D. K., Grochowski E., Cutler P. J., Paty D. W. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol. 1989 Jan;25(1):74–81. doi: 10.1002/ana.410250112. [DOI] [PubMed] [Google Scholar]
  17. Koprowski H., DeFreitas E. C., Harper M. E., Sandberg-Wollheim M., Sheremata W. A., Robert-Guroff M., Saxinger C. W., Feinberg M. B., Wong-Staal F., Gallo R. C. Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature. 1985 Nov 14;318(6042):154–160. doi: 10.1038/318154a0. [DOI] [PubMed] [Google Scholar]
  18. McFarland H. F., Frank J. A., Albert P. S., Smith M. E., Martin R., Harris J. O., Patronas N., Maloni H., McFarlin D. E. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992 Dec;32(6):758–766. doi: 10.1002/ana.410320609. [DOI] [PubMed] [Google Scholar]
  19. Miller A. E., Morgante L. A., Buchwald L. Y., Nutile S. M., Coyle P. K., Krupp L. B., Doscher C. A., Lublin F. D., Knobler R. L., Trantas F. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology. 1997 Feb;48(2):312–314. doi: 10.1212/wnl.48.2.312. [DOI] [PubMed] [Google Scholar]
  20. Perron H., Suh M., Lalande B., Gratacap B., Laurent A., Stoebner P., Seigneurin J. M. Herpes simplex virus ICP0 and ICP4 immediate early proteins strongly enhance expression of a retrovirus harboured by a leptomeningeal cell line from a patient with multiple sclerosis. J Gen Virol. 1993 Jan;74(Pt 1):65–72. doi: 10.1099/0022-1317-74-1-65. [DOI] [PubMed] [Google Scholar]
  21. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  22. Poser C. M. The epidemiology of multiple sclerosis: a general overview. Ann Neurol. 1994 Dec;36 (Suppl 2):S180–S193. doi: 10.1002/ana.410360805. [DOI] [PubMed] [Google Scholar]
  23. SIBLEY W. A., FOLEY J. M. INFECTION AND IMMUNIZATION IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:457–466. doi: 10.1111/j.1749-6632.1965.tb20229.x. [DOI] [PubMed] [Google Scholar]
  24. Sadovnick A. D., Armstrong H., Rice G. P., Bulman D., Hashimoto L., Paty D. W., Hashimoto S. A., Warren S., Hader W., Murray T. J. A population-based study of multiple sclerosis in twins: update. Ann Neurol. 1993 Mar;33(3):281–285. doi: 10.1002/ana.410330309. [DOI] [PubMed] [Google Scholar]
  25. Sibley W. A., Bamford C. R., Clark K. Clinical viral infections and multiple sclerosis. Lancet. 1985 Jun 8;1(8441):1313–1315. doi: 10.1016/S0140-6736(85)92801-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Small J. A., Scangos G. A., Cork L., Jay G., Khoury G. The early region of human papovavirus JC induces dysmyelination in transgenic mice. Cell. 1986 Jul 4;46(1):13–18. doi: 10.1016/0092-8674(86)90855-x. [DOI] [PubMed] [Google Scholar]
  27. Smith M. E., Stone L. A., Albert P. S., Frank J. A., Martin R., Armstrong M., Maloni H., McFarlin D. E., McFarland H. F. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 1993 May;33(5):480–489. doi: 10.1002/ana.410330511. [DOI] [PubMed] [Google Scholar]
  28. Souberbielle B. E., Swingler R. J., Davidson D. L., Cull R. E., Atkinson S., Davison I., Anderson J., Bell J. E., Russell W. C. Western blotting analysis in patients with MS using human brain vessels as antigen. Acta Neurol Scand. 1992 Oct;86(4):397–402. doi: 10.1111/j.1600-0404.1992.tb05107.x. [DOI] [PubMed] [Google Scholar]
  29. Souberbielle B. E., Szawlowski P. W., Russell W. C. Is there a case for a virus aetiology in multiple sclerosis? Scott Med J. 1995 Apr;40(2):55–62. doi: 10.1177/003693309504000207. [DOI] [PubMed] [Google Scholar]
  30. Stone L. A., Frank J. A., Albert P. S., Bash C., Smith M. E., Maloni H., McFarland H. F. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995 May;37(5):611–619. doi: 10.1002/ana.410370511. [DOI] [PubMed] [Google Scholar]
  31. Thompson A. J., Miller D., Youl B., MacManus D., Moore S., Kingsley D., Kendall B., Feinstein A., McDonald W. I. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 1992 Jan;42(1):60–63. doi: 10.1212/wnl.42.1.60. [DOI] [PubMed] [Google Scholar]
  32. Tienari P. J. Multiple sclerosis: multiple etiologies, multiple genes? Ann Med. 1994 Aug;26(4):259–269. doi: 10.3109/07853899409147901. [DOI] [PubMed] [Google Scholar]
  33. Warner H. B., Carp R. I. Multiple sclerosis etiology--an Epstein-Barr virus hypothesis. Med Hypotheses. 1988 Feb;25(2):93–97. doi: 10.1016/0306-9877(88)90024-2. [DOI] [PubMed] [Google Scholar]
  34. Wiebe S., Lee D. H., Karlik S. J., Hopkins M., Vandervoort M. K., Wong C. J., Hewitt L., Rice G. P., Ebers G. C., Noseworthy J. H. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol. 1992 Nov;32(5):643–650. doi: 10.1002/ana.410320507. [DOI] [PubMed] [Google Scholar]
  35. Willoughby E. W., Grochowski E., Li D. K., Oger J., Kastrukoff L. F., Paty D. W. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol. 1989 Jan;25(1):43–49. doi: 10.1002/ana.410250107. [DOI] [PubMed] [Google Scholar]
  36. Wucherpfennig K. W., Sette A., Southwood S., Oseroff C., Matsui M., Strominger J. L., Hafler D. A. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med. 1994 Jan 1;179(1):279–290. doi: 10.1084/jem.179.1.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. van Walderveen M. A., Barkhof F., Hommes O. R., Polman C. H., Tobi H., Frequin S. T., Valk J. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology. 1995 Sep;45(9):1684–1690. doi: 10.1212/wnl.45.9.1684. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES